MindBio Therapeutics Corp. MBIO

MBIO Company Overview

MindBio Therapeutics Corp. is a clinical-stage biotechnology company focused on the development of psychedelic-based therapeutics for mental health conditions. The company operates within the biopharmaceutical and mental health therapeutics industries, with a primary emphasis on researching and commercializing microdosing formulations of psychedelic compounds. Its core objective is to develop regulated, prescription-based treatments intended to address conditions such as depression, anxiety, and other neuropsychiatric disorders.

The company’s primary revenue drivers are research and development activities rather than commercial product sales, as MindBio remains in the clinical development stage. Its strategic positioning is centered on being one of the first companies to advance LSD microdosing through regulated clinical trials, which it presents as a differentiated approach compared with high-dose psychedelic therapies. MindBio Therapeutics Corp. was founded in 2019 and has evolved from an early-stage psychedelic research venture into a publicly traded entity focused on clinical validation and regulatory engagement.